Top Stories
ACTiVION-II missed the co-primary endpoints as well as secondary endpoints in osteoarthritis of the knee.
Investment in the UK biotech sector reached a five-year high in the second quarter of 2026, with total equity financing hitting £2.11 billion ($2.84 billion).
Dimerix bought MTX652, a small molecule USP30 inhibitor, from Mission Therapeutics in a deal worth up to $292 million.
Nav1.8 inhibitor LTG-001 demonstrated a roughly 50% greater analgesic effect than Vicodin in a Phase II study of patients undergoing abdominoplasty.
The firm was founded in 2020 by Jean Cui and Y. Peter Li, the small molecule experts behind Turning Point Therapeutics.
Conference News
SCOTTSDALE, Ariz., July 20, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today ...
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemothera...
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growthPresentation to include...
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional an...
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three stu...
